Kristina Bennet Emdal

Kristina Bennet Emdal

Auto-generated profile, based on publicly available information

Kristina Bennet Emdal

Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Molecular Cell
Verified
Journal Article
Closed access
CFChiara Francavilla
Chiara Francavilla
KRKristoffer T.G. Rigbolt
Kristoffer T.G. Rigbolt
KEKristina B. Emdal
Kristina B. Emdal
GCGianni Carraro
Gianni Carraro
EVErik Vernet
Erik Vernet
JOJesper V. Olsen
Jesper V. Olsen

1 January 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
ADAurelien Dugourd
Aurelien Dugourd
CKChristoph Kuppe
Christoph Kuppe
MSMarco Sciacovelli
Marco Sciacovelli
EGEnio Gjerga
Enio Gjerga
AGAttila Gabor
Attila Gabor
JSJulio Saez‐Rodriguez
Julio Saez‐Rodriguez
Multi‐omics datasets can provide molecular insights beyond the sum of individual omics. Various tools have been recently developed to integrate such datasets, but there are limited strategies to systematically extract mechanistic hypotheses from them. Here, we present COSMOS (Causal Oriented Search of Multi‐Omics Space), a method that integrates phosphoproteomics, transcriptomics, and metabolomics datasets. COSMOS combines extensive prior knowledge of signaling, metabolic, and gene regulatory networks with computational methods to estimate activities of transcription factors and kinases as well as network‐level causal reasoning. COSMOS provides mechanistic hypotheses for experimental observations across multi‐omics datasets. We applied COSMOS to a dataset comprising transcriptomics, phosphoproteomics, and metabolomics data from healthy and cancerous tissue from eleven clear cell renal cell carcinoma (ccRCC) patients. COSMOS was able to capture relevant crosstalks within and between multiple omics layers, such as known ccRCC drug targets. We expect that our freely available method will be broadly useful to extract mechanistic insights from multi‐omics studies.

1 October 2019 in Cell
Verified
Journal Article
Closed access
ALAlicia Lundby
Alicia Lundby
GFGiulia Franciosa
Giulia Franciosa
KEKristina B. Emdal
Kristina B. Emdal
JRJan C. Refsgaard
Jan C. Refsgaard
SGSebastian P. Gnosa
Sebastian P. Gnosa
JOJesper V. Olsen
Jesper V. Olsen

6 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
WHWilliam B. Hamilton
William B. Hamilton
YMYaron Mosesson
Yaron Mosesson
RMRita S. Monteiro
Rita S. Monteiro
KEKristina B. Emdal
Kristina B. Emdal
TKTeresa E. Knudsen
Teresa E. Knudsen
JBJoshua M. Brickman
Joshua M. Brickman

21 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ERElizabeth C. Randall
Elizabeth C. Randall
KEKristina B. Emdal
Kristina B. Emdal
JLJanice K. Laramy
Janice K. Laramy
MKMinjee Kim
Minjee Kim
ARAlison Roos
Alison Roos
NANathalie Y. R. Agar
Nathalie Y. R. Agar
Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and development of resistance. Elucidation of relationships among such parameters could enable the development of predictive models of drug response in patients and inform drug development. Complementary analyses were applied to a glioblastoma patient-derived xenograft model in order to quantitatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass spectrometry images of erlotinib were registered to histology and magnetic resonance images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics and immunohistochemistry were used to assess protein signaling in response to drug, and integrated with transcriptional response using mRNA sequencing. This comprehensive dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and indicates that erlotinib delivery to intracranial tumors is insufficient to inhibit EGFR tyrosine kinase signaling.

28 April 2015 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KEKristina B. Emdal
Kristina B. Emdal
APAnna-Kathrine Pedersen
Anna-Kathrine Pedersen
DBDorte B. Bekker-Jensen
Dorte B. Bekker-Jensen
KTKalliopi P. Tsafou
Kalliopi P. Tsafou
HHHeiko Horn
Heiko Horn
JOJesper V. Olsen
Jesper V. Olsen
Proteomic analysis of neurotrophin signaling identifies an inhibitory E3 ubiquitin ligase.